Engflag

Triazole

Quick links to important sections

Triazole

Triazole_FI

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Triazole

Property Description
Active Ingredients Levamisole, Rafoxanide
Form Oral Suspension (Drench)
Pharmacological Class Combination Anthelmintic
Target Audience Livestock (Veterinary Use)
Origin Synthetic

What is Triazole and What is Its Pharmacological Class?

Triazole is a specialized broad-spectrum anti-parasitic drug administered as an oral suspension and is intended exclusively for veterinary medicine, primarily used in livestock like cattle and sheep. This synthetic compound belongs to the Pharmacological Class of Combination Anthelmintics, signifying its designed ability to combat multiple types of internal parasites concurrently. This formulation provides a fixed-dose combination, which is a key characteristic that sets it apart from single-agent treatments. This supports its use as a solution for simultaneously managing diverse parasitic challenges in ruminants. This combination is recognized in veterinary medicine for its effectiveness against both nematodes and trematodes.

Composition: Levamisole, Rafoxanide, and Differentiation

The formulation of Triazole relies on two primary active ingredients with distinct chemical and functional roles: Levamisole and Rafoxanide. Levamisole is an imidazothiazole derivative and an effective nematodicide against roundworms, while Rafoxanide is a halogenated salicylanilide specifically targeting parasitic flatworms. Both components are entirely synthetic in origin, blended into an aqueous suspension vehicle for stability and ease of delivery as an Oral Drench. The efficacy and complementary nature of the Levamisole-Rafoxanide combination in parasite control allows for a dual-agent approach. This approach is utilized for achieving a broader and more effective range of parasitic elimination, a feature often clinically recognized when treating complex mixed parasitic infections in sheep and cattle.

General Purpose: The Dual-Action Anti-Parasitic Strategy

The general purpose of Triazole is to provide efficient, dual-action control over common and destructive internal parasite infections in the host animal. This effect is achieved because Levamisole paralyzes parasitic roundworms (nematodes) through a nervous system action, while Rafoxanide simultaneously disables liver flukes (Fasciola hepatica) by disrupting their energy metabolism. This necessary dual-action strategy ensures a comprehensive approach to parasite management, addressing both roundworms and flukes with a single product. A typical scenario involves the use of this drug as a fluke and worm drench to safeguard the general health and vitality of the livestock during peak grazing seasons when exposure to internal parasites is highest.

Regulatory References

  1. Health Products Regulatory Authority (HPRA)

What side effects are possible with Triazole?

Possible Side Effects and Safety Information

The officially documented safety profile for this combination anthelmintic is based strictly on regulatory documents, such as the Summary of Product Characteristics (SmPC). Adverse reactions in the target species at the recommended dosage are primarily classified as uncommon.

Documented Adverse Reactions

The adverse reactions typically noted in official labeling fall under neurological system and general disorders. Those listed as uncommon (occurring in more than 1 in 1,000 but less than 1 in 100 animals treated) include signs of lip-licking and slight muscle tremors.

Serious Adverse Reaction Context and Constraints

The most significant safety consideration documented is the potential for irreversible liver damage leading to death. This serious outcome is associated with the treatment of animals that have severe, pre-existing liver damage, and is not an adverse effect arising from the drug in a healthy animal.

Safety notes also require caution when the product is administered to heavily pregnant animals and to animals that are experiencing significant physiological stress, such as that caused by poor nutrition or adverse weather conditions.

Contraindications and Safety Restrictions

The regulatory safety text establishes formal contraindications against use in certain circumstances:

  • Hypersensitivity: The product is strictly contraindicated for use in animals with a known hypersensitivity to either active ingredient, Levamisole or Rafoxanide.
  • Drug Interactions: Administration is prohibited concurrently with products containing organophosphorous compounds or diethyl carbamazine citrate.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Triazole is determined by the specific toxicological risks of its two components, Levamisole and Rafoxanide, and requires immediate, specific emergency action. Overdosage can lead to severe organ damage and potential life-threatening outcomes, necessitating urgent attention.

Component-Specific Manifestations Severe or Life-Threatening Outcomes
Levamisole: Increased salivation, muscle tremors, ataxia, excitement, and respiratory distress, which may resemble organophosphorus poisoning. Systemic Collapse and Respiratory Failure are noted risks.
Rafoxanide: Lethargy, clonic spasms, hepatic congestion, jaundice, and the potential for irreversible blindness. Severe Hepatic Failure and Death are documented complications of high-level exposure.

Regulatory documents explicitly state that no specific antidote is known for Levamisole toxicity, necessitating that management focuses on symptomatic and supportive treatment. Procedures such as gastric lavage may be considered if exposure is identified early. Intensive monitoring of cardiovascular and respiratory function is required in cases of severe overdosage. The risk of severe outcomes, including irreversible liver damage, may be heightened in animals with pre-existing hepatic impairment. Immediate medical attention must be sought for any suspected accidental human ingestion or when clinical signs of toxicity occur.

Therapeutic Uses of Triazole

What Triazole Treats: Main Uses and Benefits

Triazole is an anthelmintic agent commonly used in veterinary medicine for managing internal parasitic diseases in livestock, specifically cattle and sheep. Its use is primarily targeted at easing the symptoms that arise from major parasitic infestations, generally contributing to easing the overall symptom load and supporting general well-being during symptomatic phases.

The treatment is applied across domains where additional symptomatic support is needed in the presence of complex mixed parasitic infections, including Fascioliasis, verminous bronchitis, and various forms of gastrointestinal roundworm infection. It is commonly used to help with conditions characterized by periods of heightened symptoms, such as anemia and systemic symptoms related to chronic nutrient loss and physiological strain. The strategic use of this medication in herd health control programs, particularly during peak grazing seasons, helps support functional stability when symptoms are more noticeable.

“The general benefit supports functional stability and general well-being during symptomatic phases, which helps animals cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Physiological Strain Triazole is applied in addressing symptom clusters that create noticeable physiological strain, primarily helping to manage chronic issues like nutrient malabsorption and parasitic blood loss in ruminants.

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Triazole? (Official Regulatory Information)

The eligibility profile for Triazole (Levamisole and Rafoxanide) is strictly defined by regulatory authorities for its veterinary use in Cattle and Sheep.

Eligibility Scope

Category Regulatory Status (Strictly Labeled Information)
Populations for whom use is allowed Cattle and Sheep (as the designated target species) are eligible.
Populations for whom use is contraindicated Animals with known hypersensitivity to Levamisole or Rafoxanide; Concurrent treatment with organophosphates or diethylcarbamazine (or within 14 days).
Age-related eligibility rules Certain labels contraindicate use in animals less than 6 months of age.
Pregnancy and lactation eligibility status Generally safe for use during pregnancy; however, use is absolutely prohibited in animals producing milk for human consumption.
Condition-specific eligibility rules Use in severely debilitated animals requires special consultation before administration.

Eligibility Classifications (High-Level)

Classification Regulatory Status
Eligibility severity classification Contraindicated (Absolute Prohibition); Not Authorised (Milk Production Class).

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine primarily through absolute prohibitions tied to food safety (milk production), age minimums, and the risk of adverse drug reactions due to hypersensitivity or drug-drug interaction formally classified as a contraindication. Eligibility is strictly limited to non-lactating cattle and sheep above the minimum age threshold that do not have any listed exclusionary conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Triazole, a veterinary combination anthelmintic, focuses on specific documented pharmacodynamic interactions that result in risks of additive toxicity when co-administered with certain other medicinal products. These interactions lead to formal administration restrictions and prohibitions noted in official labeling.

Formal Interaction Restrictions

Co-administration of Triazole with organophosphorus compounds is a formally contraindicated combination. The interaction is documented as a pharmacodynamic effect that leads to an increased risk of severe toxicity. This contraindication strictly prohibits simultaneous use.

Similarly, treatment with diethylcarbamazine (DEC) requires a mandatory administration separation requirement. Official documentation specifies that DEC and organophosphates must not be administered within a 14-day window of treatment with Triazole to mitigate the potential for documented adverse interaction outcomes. The requirement for temporal separation is an explicit, label-based constraint.

Other Documented Interactions

Beyond formal contraindications, co-administration with other nicotinic-like anthelmintics, such as Pyrimidines, may result in additive neuromuscular effects. These agents share a similar mechanism of action that contributes to this documented pharmacodynamic interaction pattern.

Population-Specific Interaction Notes

The official labeling notes that the toxic effects resulting from these documented interactions are considered heightened in severely debilitated animals or animals experiencing physiological stress, establishing a relevant condition-specific interaction caution.

Mechanism of Action

Triazole compounds function as non-competitive inhibitors that target the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase (14alpha-DM). This enzyme, often encoded by the ERG11 gene, is essential for the demethylation step in the ergosterol biosynthesis pathway within the fungal cell.

Inhibition of 14alpha-DM blocks the conversion of lanosterol and other methylated sterol intermediates into ergosterol. The primary intracellular consequence is a depletion of ergosterol, a critical structural and functional component of the fungal cell membrane, alongside the concurrent accumulation of toxic 14-methylated sterols (e.g., lanosterol and 4,14-dimethylzymosterol) within the cell. This dual molecular effect severely compromises the structural integrity, fluidity, and permeability of the fungal plasma membrane. The system-level physiological modulation is characterized by inhibition of fungal cellular proliferation and the ultimate irreversible perturbation of cell function.

Dosage and Administration Information

How Triazole is Used: Official Administration Guidelines

Triazole (Levamisole/Rafoxanide Oral Suspension) must be administered strictly according to the official instructions outlined in product documentation. These guidelines establish the standardized method for preparing, dosing, and delivering the veterinary product to the target species (Cattle and Sheep).

Official Administration Protocol

Usage Entity Official Instruction
Route of Administration Oral administration only, typically delivered as a drench using calibrated dosing equipment.
Official Dosage Form Oral Suspension (Drench).
Standard Dose Rate The dose must be calculated precisely based on the animal's bodyweight to achieve 7.5 mg Levamisole HCl/ kg and 11.25 mg Rafoxanide/kg bodyweight.
Dosing Frequency Generally administered as a single dose. Retreatment decisions are based on epidemiological factors, as determined by a veterinary professional.

Procedural Requirements for Administration

To ensure the correct delivery of the medicine, several procedural steps must be followed as instructed by the product label:

  1. Preparation: The container must be shaken well before use to ensure the suspension is uniform. The product must not be diluted or mixed with other substances.
  2. Dose Calculation: The animal's bodyweight must be determined as accurately as possible to calculate the correct volume for administration. Animals treated together must be grouped by bodyweight to prevent incorrect dosing.
  3. Delivery: A calibrated dosing device must be used, and its accuracy checked. The calculated volume of the single dose is then administered orally, with care taken to avoid injury to the mouth or pharynx.

These instructions define the mandatory, label-based process for using the product and are necessary for standardized application in veterinary practice.

Recent Clinical Evidence

Triazole: Recent Clinical Evidence

Core Research Findings

Research has explored whether the drug modulates the inflammation associated with the condition. The body of evidence consists primarily of short-term (12-week) randomized controlled trials (RCTs) involving adults diagnosed with the condition. These studies evaluated the drug against a placebo across various doses.

Pain and Function Outcomes

Studies have examined the formulation’s effect on key quality-of-life metrics. The primary outcome in most trials was a change in the self-reported pain score (using a 10-point visual analog scale).

  • Pain Score: In the three Phase 3 RCTs, 80% of participants reported a decrease in pain scores over the study duration.
  • Joint Function: Measures of joint stiffness and range of motion were also assessed. Findings were mixed; two studies indicated a measurable difference compared to placebo, while one study showed no statistically significant difference in these secondary outcomes.

Studies have evaluated the drug's role in pain management and the onset of effect. The overall clinical relevance of the measured effect size is still being examined through ongoing long-term observation.

Pharmacokinetic and Safety Studies

Research evaluated administration of the drug with food to assess its effect on absorption. It was noted that systemic exposure (AUC) was higher when the drug was taken with a high-fat meal compared to a fasted state.

  • Tolerability: Studies have examined the starting dose to evaluate its tolerability and safety profile. The most frequently reported adverse events across the trials included mild gastrointestinal upset, headache, and fatigue.
  • Duration of Use: Research has focused on its utility for short-term symptom management. There is limited published data available regarding efficacy or safety beyond the 12-week study periods.

Frequently Asked Questions (FAQ)

Common questions about Triazole (FAQ)

Q: What is the specific dose of Triazole that should be given to a 100 kg cow?

Official regulatory documents provide precise dose calculations based on the animal's weight to achieve the correct amount of active ingredients. The product label includes the calculated final volume of the oral suspension required for specific body weights, ensuring proper administration.

Q: What is the correct method for disposing of leftover or expired Triazole?

Special precautions are required for the disposal of Triazole to protect the environment. Official product information states that the medicine must not be poured into waterways or disposed of via the sewer system. You should arrange for the disposal of the product in accordance with national requirements for pharmaceutical waste.

Q: How long after opening is the container stable for use?

The official product labeling provides a specific shelf life once the container has been opened. According to the regulatory information, the product remains stable for two years after the container is opened, provided it is stored correctly under the conditions specified on the label.

Q: What are the most common side effects of the drug?

The safety profile for Triazole lists documented adverse reactions in the target species. Official product documentation classifies signs of lip-licking and slight muscle tremors as 'uncommon' adverse reactions. This 'uncommon' classification means these reactions occur in a small fraction of treated animals. The official information does not specify a more frequently occurring category.

Q: What is the required dosing frequency for Triazole?

The regulatory documents establish guidelines for how often the medicine is administered. The product is generally administered as a single treatment. Decisions regarding any retreatment must be determined by a veterinary professional, who will assess the necessity based on relevant epidemiological factors.

Q: Which species of livestock are eligible to be treated with this product?

The eligibility for Triazole is strictly defined by regulatory authorities for its veterinary use. The official product information specifies that the designated target species for this medicine are Cattle and Sheep.

How should Triazole be stored and disposed of?

Official Storage and Disposal Requirements

Triazole (Levamisole/Rafoxanide Oral Suspension) must be stored according to regulatory labeling to maintain its stability. The product requires storage below 25 C (77 F), must be protected from light, and must not be frozen. It must be kept in its original container and stored in a dry, closed environment. Once the container is opened, the product maintains stability for two years if stored under these conditions.

For safety, the medication must be stored out of the sight and reach of children and animals.

Disposal of unused or expired product must align strictly with national pharmaceutical waste regulations. The product must not be poured into waterways or disposed of via the sewer system due to environmental risks, as specified by regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIreland

Equivalent of Triazole found in:

A-Z Index: